



Leveraging AI for the Diagnosis and Management of Mental Health Disorders: Opportunities and Challenges

Manisha Patil¹, Geetanjali Sharma¹, Rahee Walambe^{1*}

¹ Symbiosis Institute of Technology, Symbiosis International (Deemed University), Lavale, Pune 412115, Maharashtra, India.

*rahee.walambe@gmail.com

Abstract. Mental health problems such as depression, anxiety, schizophrenia, and Alzheimer's disease continue to present significant challenges due to their delayed detection, lack of clinical resources, and subjective diagnosis methods. Detection of these diseases in their early stages becomes very crucial for clinicians to advise them with the treatments. But with clinical tests it becomes very difficult to identify them at early stages. By introducing AI in detection of mental health disorders, it gives a path to early detection. Rather than using single modality to screening, diagnosis by investigating multiple modalities gives promising results. This research aims to investigate the possible advantages of multimodal data integration for the early diagnosis, screening, and continuous monitoring of mental health disorders using artificial intelligence. The literature review includes peer-reviewed articles on digital phenotyping, machine learning, deep learning, natural language processing, neuroimaging, and voice analysis. The findings of this research show that AI models are 10-15% more accurate than traditional methods for the diagnosis of cognitive decline from behavioral and sensor data, schizophrenia from MRI scans, and depression from voice characteristics.

Keywords: Artificial Intelligence, Mental Health, Multimodal Deep Learning, Early Diagnosis, Ethical AI.

1 Introduction

Mental health disorders like depression, anxiety, schizophrenia, and Alzheimer's disease are some of the leading causes of disability worldwide, affecting almost one billion people every year [1]. The traditional methods of diagnosis have relied on interviews, psychometric tests, and subjective reporting. These are inherently prone to subjective interpretation and may lead to delays or inconsistencies in diagnosis. Because of the shortage of qualified mental health professionals worldwide, especially in resource-poor settings, there has been an urgent need for innovative solutions that can enable early detection, objective assessment, and scalability. In the past few decades, the development of Artificial Intelligence (AI) has brought about a paradigm shift in the measurement, monitoring, and treatment of mental health. The potential of AI algorithms, especially those that involve machine learning, natural language

processing, and computer vision, is to analyze complex multimodal data (such as text, speech, facial expressions, and physiological signals) and detect subtle patterns that are indicative of mental health states. Early studies showed the potential of using support vector machines and decision trees to classify clinical depression based on questionnaire responses. Later studies have investigated the use of deep learning models based on smartphone usage patterns, social media text, and passive sensory data to predict the onset or relapse of mental health conditions.

Artificial Intelligence (AI) has emerged as a revolutionary tool in the medical field, offering strong tools for the analysis of complex multimodal data. Recent studies have demonstrated that AI can uncover hidden patterns in speech, text, neuroimaging, and behavioral data that are not easily observable by medical professionals. For instance, Esteva et al. emphasized the capability of deep learning algorithms to perform at or beyond the level of human experts in the domain of medical diagnosis [2]. Similarly, Shatte et al. emphasized the capability of machine learning to detect risk factors for depression and anxiety with greater accuracy than traditional methods [3]. Kalmady et al. demonstrated the capability of deep learning algorithms to distinguish patients with schizophrenia from healthy controls with high accuracy using MRI scans [4]. Moreover, the integration of AI-powered chatbots and digital interventions, such as Woebot and Wysa, has demonstrated potential for delivering scalable and accessible mental health support [5]. Despite these advances, challenges remain in ensuring data privacy, reducing algorithmic bias, and achieving clinical explainability and acceptance. The traditional method for the clinical diagnosis of mental illnesses has been based on the experience of the practitioner, interviews, and psychometric tests (like PHQ-9 and GAD-7). Although this method is still the norm, some drawbacks are being experienced at the current stage. The diagnosis is largely dependent on the patient's self-reporting and the clinician's interpretation, which could be prone to errors. Symptoms are generally identified only after a considerable deterioration, which leaves very little scope for early intervention. The current lack of mental health professionals worldwide makes it difficult to have an early diagnosis, particularly in resource-poor settings. It is not possible to devote sufficient clinician time to diagnostic interviews for large numbers of people. Together with clinical diagnosis, Artificial Intelligence (AI) fills these gaps by offering objective, scalable, and sustained support. AI can look for minute differences in speech, text, behavior, or smartphone sensor data that lead to clinically visible symptoms. This helps in the early detection of at-risk cases before the condition deteriorates. Machine learning models can identify hidden patterns in multimodal data (such as speech, facial expressions, and mobility) that could be missed during routine testing. AI-driven tools (such as chatbots and mobile sensing applications) help in screening in underserved communities, thus reducing the diagnostic gap. AI supports the capabilities of healthcare professionals rather than replacing them. AI can identify potential cases, prioritize high-risk individuals, and provide interpretability through Explainable AI (XAI). In contrast to personal medical consultations, AI models enable the continuous observation of patients, providing medical professionals with longitudinal information that can help with diagnosis and treatment plan modification. AI ensures consistency in evaluation, thus minimizing variability in the results of medical professionals. The objective of this study is to

integrate recent advances in the application of AI for mental health conditions, evaluate their efficacy, and develop a framework for implementing multimodal AI tools in the medical field. This study helps in the development of trustworthy and patient-centric AI solutions for mental health care by connecting ethics with innovation.

2 Review of Literature

This paper adopts the scoping and narrative review approaches to review recent literature on artificial intelligence techniques for the diagnosis and treatment of mental health issues. The literature review adopted the use of key scientific databases like IEEE Xplore, PubMed, Scopus, and Google Scholar. Articles of relevance that were published in the past few years were identified using keyword searches that included mental health, artificial intelligence, machine learning, deep learning, depression, anxiety, EEG, neuroimaging, speech analysis, and natural language processing. Articles that highlighted the use of AI techniques for the diagnosis, screening, or monitoring of mental health were considered. Both unimodal and multimodal techniques were considered. To ensure comprehensive coverage of the different data modalities, review articles, methodological articles, and representative application studies were considered. Articles that focused on applications of AI in other fields and not mental health were excluded. Li and colleagues synthesized randomized and non-randomized experimental studies to evaluate the effects of AI-based conversational agents (CAs) on psychological distress and well-being in a systematic review and meta-analysis of CAs for mental health interventions. Methodology used in this study performs extensive database search, selection of experimental studies with AI-based CAs as the main interventions, quantitative meta-analysis, and narrative synthesis of user-experience elements. As a result, the authors point out gaps in the assessment of contemporary AI-based (non-rule) systems and suggest higher-quality RCTs. They also report modest but statistically significant improvements in some mental health outcomes, with heterogeneity driven by CA type, study quality, and population [6]. In naturalistic settings, Riad et al. investigated the predictive ability of speech data collected by mobile devices to identify symptoms of anxiety, depression, exhaustion, and insomnia. Approach used in this study is to collect short, prompted speech samples using mobile devices then prosodic and acoustic features are extracted, supervised machine learning classifiers are trained, and cross-validation is performed. The study's authors stress the importance of robustness checks and the need for varied, longitudinal speech datasets. They found that speech-derived features produced meaningful predictive signals for depression and fatigue (AUCs in a clinically useful range), while signals for anxiety and insomnia were weaker [7]. Shen and collaborators systematically reviewed passive sensing studies (smartphones and wearables) that applied ML to monitor clinically diagnosed mental health conditions. The study aims at systematic search through peer-reviewed literature, extraction of feature types (GPS, accelerometry, screen/app use, HRV), and evaluation of ML methods and validation approaches. The review found consistent associations between mobility/sleep patterns and depressive symptoms and that ML models often achieved moderate discrimination;

however, methodological heterogeneity, limited external validation, and inconsistent reporting of fairness/privacy practices were major limitations [8].

This workshop-based report synthesizes expert recommendations for improving rigor, equity, and impact of digital sensing tools in mental health research. **Methodology:** Proceedings from a multi-stakeholder workshop (researchers, clinicians, ethicists) culminating in best-practice guidance. Key recommendations include standardizing feature definitions, prioritizing cross-platform data availability, embedding fairness audits, adopting privacy-preserving pipelines, and building longitudinal, representative cohorts to improve generalizability. The report functions as a field roadmap rather than an empirical study [9]. Bauer et al. evaluated machine-learning models applied to clinical speech recordings for monitoring Major Depressive Disorder (MDD). **Methodology** includes Clinical speech data collection across repeated visits, feature extraction (spectral/prosodic), supervised modelling, and assessments of longitudinal prediction. As a result of the study ML models could track symptom changes over time with acceptable accuracy and offered potential for long-term monitoring, authors emphasize need for calibration, prospective validation, and integration with clinician workflows [10]. Ahmed and coauthors developed a minimal, rapid system for detecting probable depression from short-duration data collection designed for real-world screening. **Methodology** is to design a lightweight pipeline extracting quickly obtainable features (brief questionnaires + minimal sensor signals), training classifiers, and evaluating performance and response time. The minimal system produced competitive accuracy for screening use-cases while dramatically reducing data-collection time, suggesting feasibility for low-burden triage in large populations; authors note trade-offs between speed and depth of assessment [11]. Wang et al. systematically reviewed multimodal AI approaches (EEG, eye movement, audio/video, gait) for depression screening and synthesized classification performance across modalities. The study performs systematic literature search, extraction of reported classifier metrics and modality-specific pipelines, meta-analytic synthesis where possible. Multimodal systems generally outperformed uni-modal counterparts, especially when physiological signals complemented behavioral data; heterogeneity and small sample sizes limit firm clinical conclusions—authors call for standardized benchmarks and larger samples [12]. To predict the severity of depression in clinical and community cohorts, Karlin and colleagues assessed machine learning models that combined semantic and acoustic speech features. Using supervised regression/classification models, cross-cohort validation, transformer-derived embeddings and acoustic features, and speech sample collection the article assessed machine learning models. **Results:** The study demonstrates the difficulties in generalizability when transferring between clinical and community samples. Multimodal speech models outperformed acoustic-only baselines in severity estimation, obtaining higher correlations with clinician-rated scales [13]. Torous et al. address translational barriers and offer a comprehensive summary of the data supporting digital mental health (apps, digital therapies, sensing, and AI). **Approach:** narrative analysis of current empirical and policy research evaluating the practical application and scientific underpinnings. **Results:** The review highlights encouraging initial findings for AI-assisted screening and low-intensity support, but it also points

out enduring issues, such as a lack of clinical trials showing improved outcomes, unclear regulations, privacy concerns, and uneven clinical practice adoption [14].

This systematic review summarizes the use of AI in mental health diagnosis, monitoring, and intervention across a wide range of modalities and conditions. Through qualitative synthesis of domains, methods, and ethical issues by applying extensive database search and with inclusion of criteria centered on AI applications in mental health care. Major findings of study can be listed as , AI has demonstrated promise in several tasks and proof-of-concept successes; however, it is still constrained by a variety of study designs, insufficient external validation, and inconsistent reporting on privacy protections and bias mitigation. The authors offer suggestions for upcoming excellent trials and governance structures [15]. Huang et al. addressed data scarcity through transfer learning by using a pretrained wav2vec 2.0 model as an audio feature extractor for depression detection from voice recordings. To identify depression at early stages the study performs training downstream classifiers, assessing cross-corpus robustness, and fine-tuning wav2vec 2.0 embeddings on speech corpora with depression labels. Transfer learning is useful for small clinical datasets, as evidenced by the pretrained audio-encoder approach's higher detection accuracy over handcrafted acoustic features. The authors advise using larger, more diverse corpora for additional benefits [16]. Olawade and associates examine current developments, moral dilemmas, and potential paths for incorporating AI into mental health treatment. Thematic synthesis of governance topics and technological advancements (NLP, ML, digital phenotyping) combined with a narrative review of peer-reviewed literature. The study identifies key obstacles (data governance, model interpretability, health inequities) and opportunities (scalable screening, personalized digital therapeutics). It also suggests standard reporting and interdisciplinary cooperation [17]. Teferri and colleagues reviewed NLP techniques for identifying depression in clinical texts and social media, talking about methodological limitations, ethical concerns, and achievements. The approach used is systematic review of literature with a focus on models, datasets, evaluation metrics, and features (lexical, syntactic, and transformer embeddings). Major findings of the study are clinical translation is still hampered by dataset biases, platform domain shifts, and privacy/consent issues, even though transformer-based embeddings and fine-tuning improved classification over previous bag-of-words techniques [18]. To differentiate depressed from non-depressed people and stratify severity, this JMIR Mental Health study suggested an interpretable framework that combines uncertainty quantification with feature-level explanations (SHAP/attention). Methods: Multimodal model trained on text/speech features; post-hoc XAI methods; clinician assessment of the utility of the explanation. Findings: The authors recommend XAI coupling with calibration for clinical deployment, as the interpretable pipeline maintained competitive predictive performance while boosting clinician-perceived trust and actionable understanding [19]. Liu and colleagues pooled studies that applied DL architecture to voice data in order to meta-analyze deep-learning diagnostic accuracy using speech for depression detection. Methods: systematic search, evaluation of study quality, pooled diagnostic metrics (AUC, sensitivity/specificity), and subgroup analyses by preprocessing and dataset. Findings: DL models showed encouraging pooled accuracy, but they were plagued by high heterogeneity and publication bias. The

authors advocate for larger datasets, open-code practices, and standardized benchmarks [20]. Kapitány-Fövény and colleagues compared inner versus overt speech conditions and examined EEG markers and machine learning classification between depressed patients and controls. Methods used are ML classification with cross-validation, spectral/microstate feature extraction, and EEG recording under task conditions. Results: The study indicates that EEG is still a promising but technically challenging biomarker that needs more extensive replication studies. Specific EEG microstate features and spectral patterns were found to discriminate against depressed participants, with inner-speech conditions displaying different patterns [21]. Aledavood and associates examined phone screen/app use, communication, sleep, mobility, and physical activity in a multimodal, long-term digital phenotyping study of patients with major depression. Methodology: Using clinician-rated symptom assessments and prospective passive data collection, feature engineering and machine learning modeling are used to forecast symptom fluctuations. Results: For short-term symptom changes, combined behavioral features had a strong predictive value; the authors stress that completeness of data and personalization are important aspects of model performance. Khoo et al. synthesized popular feature extraction techniques, fusion strategies, and evaluation practices in their systematic review of 184 studies on multimodal machine learning approaches for mental health detection. Methodology: Comprehensive analysis of text, audio, video, wearable, and smartphone data sources, along with a taxonomy of fusion techniques and a quality evaluation. Results: The review concluded that while multimodal fusion frequently enhances detection, reproducibility is hampered by inconsistent reporting, handling of missing data, and small sample sizes. The authors suggest standardized pipelines and fairness reporting. Menne et al. looked into the differences in speech characteristics between people with Major Depressive Disorder (MDD) and healthy controls, as well as how these differences related to the severity of symptoms. Methods: ML classification, correlation with clinical scales, thorough acoustic/linguistic feature extraction, and cross-sectional clinical sample. Findings: Compared to the baseline, classification improved and certain prosodic and spectral features were associated with severity; for increased robustness, the authors suggest combining speech and behavioral measures. To determine which smartphone sensor modalities are frequently utilized in mental health monitoring, Leimhofer and colleagues synthesized reviews. They then used PhoneDB to evaluate cross-platform availability. Methodology: empirical inventory of sensor access across devices and operating systems combined with an umbrella review. Findings: Although key sensors (accelerometer, GPS, screen events) are widely accessible, cross-study harmonization is complicated by platform variability and privacy restrictions; the paper offers helpful advice for study designers.

Based on the current literature available it has been observed that there is a lot of research and study is going on to identify various mental health disorders in its early stages. Which can be helpful to rescue the patient early and help recover from these disorders. As it is difficult to identify mental health disorders based on clinical data these studies also help clinical practitioners to identify the disease accurately to plan the treatment for such patients. Now next section will introduce the methodology being used in the studies performed till now to address these mental health challenges.

3 Review of methodology

As per the studies performed for the identification of mental health disorders, we used various methods based on diverse modalities from neuroimaging and electrophysiology (high-signal biological biomarkers) to speech, sensor, and social-media traces (low-cost, scalable behavioral markers). This section represents the summary of studies performed based on methodological strengths.

3.1 Clinical neuroimaging (MRI, fMRI, PET)

For the objective detection and classification of neurodegenerative diseases, especially Alzheimer's disease (AD), neuroimaging remains a crucial technique. Research uses PET (amyloid/tau levels), functional MRI (connectivity analysis), and structural MRI (volumetric analysis, cortical thickness measurements) as data for traditional machine learning and deep learning workflows. Convolutional neural networks (CNNs), transfer learning, and hybrid architectures used in MRI/PET for AD classification and MCI→AD conversion prediction are highlighted in recent studies. Conventional pipelines apply CNNs or ensemble classifiers after performing image preprocessing (bias correction, registration, skull-stripping), extracting features from ROI, or using voxel-wise inputs [22].

3.2 EEG and quick brainwave and cognition tests

EEG-based techniques examine event-related potentials, connectivity, and spectral characteristics (power ratios, slowness). EEG data or time-frequency representations are used to train ML classifiers (SVMs, RFs) and DL models (1D/2D CNNs) for early AD or MCI identification. Although more extensive validation is required, recent experiments investigating short passive EEG activities for screening (such as the Fastball test) indicate potential as inexpensive, scalable early-risk signals. [23].

3.3 Digital phenotyping using sensors from smartphones and wearables

Both active assessments (ecological momentary assessment) and passive sensing (GPS, accelerometer, screen time, call/SMS metadata, typing dynamics) are used to infer behavioral indicators for depression, anxiety, relapse risk, and early warning signals. Raw sensor streams are usually combined into daily/week-level features (mobility, sleep estimates, social activity proxies) by pipelines for temporal modeling. These features are then fed into LSTM networks, random forests, or gradient boosting. Reviews highlight helpful predictive indicators while emphasizing privacy and consent issues. [24].

3.4 Electronic health records (EHR) and administrative data

EHRs supply structured diagnoses, lab/test results, medication histories, and clinical notes. Approaches combine feature engineering from structured fields, NLP on clinical notes, and temporal models (time-aware XGBoost, RNNs, transformer architectures) to predict onset or relapse. EHR studies are powerful for scale but face coding heterogeneity and temporal shift across institutions [25].

3.5 Speech and voice biomarkers

Many studies have examined speech traits related to depression and cognitive decline, including prosody, articulation, pause patterns, and lexical/semantic content. Feature extraction pipelines include end-to-end transformer models trained on tokenized transcripts or spectrograms, as well as hand-crafted linguistic and acoustic features. Speech has been decline predict amyloid status, symptom severity, and early cognitive decline; however, recording conditions and cohort heterogeneity have a substantial effect on performance [26].

Table 1. Comparative Analysis of AI-Based Modalities for Mental Health Detection

Modality	Data Type	AI Techniques	Mental Health Targets	Strengths	Limitations / Challenges
Neuroimaging (fMRI, MRI, PET)	Brain scans (volumetric / functional)	CNNs, 3D-CNNs, SVM, Deep learning	Schizophrenia, Depression, Autism, Bipolar	High spatial resolution; detects structural/functional biomarkers	High cost; limited accessibility; requires expert preprocessing; small datasets
Electroencephalography (EEG)	Electrical brain activity	RNNs/LSTM, CNN, Feature extraction + ML	ADHD, Depression, Epilepsy-related mood dysregulation	Excellent temporal resolution; portable devices	Prone to noise/artifact; complex signal preprocessing; lower spatial specificity
Speech / Voice Analysis	Acoustic features (pitch, tone, prosody)	SVM, Random Forest, Deep learning	Depression, Anxiety, PTSD, Schizophrenia	Non-invasive; can be continuous/remote; scalable	Affected by language, recording quality; cultural bias
Text / Natural Language Processing (NLP)	Written / spoken transcripts	Transformers (BERT), LSTM, Sentiment analysis	Depression, Suicidality, PTSD, Bipolar	Leverages large datasets; interpretable patterns	Privacy concerns; linguistic/cultural variations; annotation bias
Facial Expression / Video Analysis	Facial cues, micro-expressions	CNNs, Pose estimation, RNNs	Depression, Autism Spectrum, Anxiety	Immediate signs of affective state	Lighting/pose variability; masking of true emotions

Wearable Sensors (Physiological)	Heart rate, sleep, movement, GSR	Time series ML, Deep learning	Stress, Anxiety, Mood disorders	Real-time monitoring; objective indicators	Wearable adherence; noise; data privacy
Social Media / Digital Trace Data	Posts, interaction patterns, typing behavior	Graph models, NLP, ML classifiers	Depression, Suicide risk, Anxiety	Large scalable data; longitudinal signals	Ethical concerns; self-selection bias
Biomarkers / Genomics	Genetic variants, blood markers	Ensemble ML, Neural networks	Risk prediction (e.g., depression, schizophrenia)	Can reveal biological predispositions	Complex interplay; expensive; interpretability issues

3.6 **Multimodal Fusion**

In recent years, multimodal fusion, the synergistic integration of diverse data types such as speech and text, physiological/behavioral sensors, neuroimaging, and clinical records—has gained increasing importance in capturing the complex, multifaceted nature of mental health disorders such as depression, anxiety, and early neurocognitive decline. When audio-linguistic traits were combined with facial, posture, and wearable sensor streams, for example, stress was detected with over 95% accuracy, demonstrating the power of behavioral + physiological fusion [27]. Another study that thoroughly examined 184 passive-sensing multimodal research (smartphones, wearables, audio/video) found that models with cross-modal linkages performed better than unimodal ones [28]. Deep learning frameworks that employed cross-attention between text and audio modalities achieved 94.9% accuracy in depression identification when compared to simple concatenation algorithms [20]. However, multimodal models face major challenges, such as missing-modality data, heterogeneous signal alignment, large sample requirements, model interpretability, and privacy/consent concerns, even though they are better able to capture the diversity of mental disorders [29,30]. Thus, multimodal fusion offers a promising path toward early detection; however, careful attention to methodological standardization, external validation, and ethical considerations is essential to transforming such models into clinically ready tools.

3.7 **Various Fusion Strategies**

Early Fusion: To concatenate features from modalities into one vector before modeling. It is simple, captures cross-feature interactions directly. But it is Sensitive to scale/temporal alignment and missing modalities; can explode dimensionality.

Intermediate: Learn modality-specific representations then fuse via attention, cross-modal transformers or joint latent spaces. It has shown best performance on complex tasks. Models cross-modal interactions are done richly. Shows good interpretability via attention. But computationally costly, higher engineering complexity.

Late Fusion: Train separate unimodal models, combine outputs (avg, weighted, meta-learner). Robust when modalities missing; modular; easier debugging per modality.

Chances to miss deep cross-modal feature interactions. needs good per-modal classifiers.

4 Challenges and Opportunities of AI-Based Mental Health Systems

4.1 Challenges faced in implementation of AI- Based Mental Health Systems

Lack of annotations, heterogeneity, and quality of data: Mental health data can be obtained from clinical notes, images, speech, and self-reporting, among many other sources. The quality and format of the data may also be highly heterogeneous. Moreover, due to the cost of annotations and privacy issues, high-quality annotations from experts are difficult to obtain.

Population Bias and Generalizability: The AI models that were trained on specific populations were not able to generalize well to other settings. Biases in training data can result in discriminatory outcomes and the propagation of injustices.

Privacy and Ethical Considerations: Consent, security, and secondary use without the patient's knowledge are only a few ethical considerations that must be taken into account when dealing with sensitive mental health information. The well-being of patients can be adversely affected due to violations

Validation and Clinical Integration: Because of differences in data gathering and clinical practices, AI models are often validated on controlled data but fail to perform well in actual clinical settings.

Legal and Regulatory Difficulties: Accountability, liability, and clinical certification are some of the challenges posed by the lack of clear regulatory guidelines on the application of AI in mental health practice

4.2 Opportunities for AI- Based Mental Health Systems:

Though the challenges exist AI based mental health systems offer many opportunities also.

Integration of Multiple modalities: AI gives an opportunity to analyze mental health disorders by combining various modalities such as neuro imaging, speech or language features, clinical histories and genetic information of a patient to improve early detection and prognosis of conditions like Alzheimer's and depression.

Early Identification: By implementing AI for diagnosis of mental health disorders, it is expected to detect the mental health disorders at their early stages. Where patients can be monitored with wearables and can towards patient betterment.

Personalized Treatments: Deep learning can enable personalized care for mental health patients by learning the patterns of symptoms and responses to treatment for everyone, allowing for precise mental health interventions.

Privacy-Preserving Learning Methods: Decentralized machine learning approach that trains algorithms on multiple devices or servers (edge devices) holding local data samples, without exchanging the raw data.

Scalable Mental Health Support: Mental health AI applications can be used to provide scalable mental health support in underserved areas by augmenting clinician capacity and offering scalable screening tools

Human-in-the-Loop Decision Support: Incorporating clinician input into AI systems can ensure that the final outcome is clinically verified, combining the strengths of human and computational intelligence.

5 Review of results

Recent empirical research has demonstrated that AI techniques can accurately identify and forecast a wide range of mental health issues; however, performance and clinical preparedness vary significantly depending on the model class, evaluation rigor, and data modality. Neuroimaging-based classifiers (MRI, PET) and combined MRI/PET fusion approaches are frequently reported to have the best discriminative performance for Alzheimer's disease and MCI→AD conversion. In retrospective cohorts, advanced CNNs and ensemble models perform better than classical baselines; however, there is still a lack of prospective and multi-site validation [31, 32, 33]. Speech and language models, ranging from acoustic-feature + classical classifiers to transformer fine-tuning on transcripts, consistently show utility for screening for depression and cognitive decline and often produce clinically significant correlations with biomarkers and symptom severity in held-out test sets [20].

EEG and brief electrophysiological paradigms show promise for detecting early cognitive impairment in pilot studies, particularly when combined with ML feature selection; however, sample sizes are typically small, and artifact control is essential [36]. Models that combine mobility, sleep, and usage metrics perform better than single-feature predictors in longitudinal studies; however, handling missing sensor streams and calibrating the model are frequent issues [34, 35]. Strong indicators of behavioral change that are predictive of mood episodes and relapse risk are produced by passive digital phenotyping (smartphone sensors, wearables). Scalable predictions for suicide and relapse risk are provided by many EHR-based risk models, despite the fact that they lack the PPV, calibration, or external validation necessary for implementation and have high discrimination on internal splits [34].

When compared to unimodal baselines, multimodal fusion techniques (early, late, and hybrid) generally improve accuracy and robustness while lowering single-source noise. This is particularly true for hybrid attention-based architectures that learn cross-modal interactions, but they also require larger, more carefully selected cohorts and come with additional privacy and engineering complexity [31, 32, 20]. Despite promising retrospective results, the main gaps across methods that collectively limit clinical translation are limited prospective/external testing, inconsistent ethical/privacy disclosures, inadequate reporting of calibration and clinical thresholds (PPV, decision curves), and inadequate fairness/subgroup analyses [35, 31, 33].

5.1 Statistical analysis

Table 2. Statistical analysis of Performance Metrics, Comparison Methods and Validation

Strategies			
Aspect	Category	Methods / Measures Commonly Used in Reviewed Studies	Purpose in Mental Health AI Studies
Performance metrics	Classification metrics	Accuracy, Precision, Recall (Sensitivity), Specificity, F1-score	Evaluate diagnostic performance for disorders such as depression, anxiety, schizophrenia, and bipolar disorder
	Discriminative metrics	AUC-ROC, sometimes AUC-PR	Assess model's ability to distinguish between healthy and affected subjects, especially under class imbalance
	Multi-class evaluation	Macro-F1, Weighted-F1, Macro-precision, Macro-recall	Fair evaluation when multiple mental health conditions are predicted simultaneously
	Regression metrics (severity / risk prediction)	MAE, RMSE, R ²	Evaluate symptom severity estimation, progression tracking, or relapse risk prediction
	Error analysis tools	Confusion matrix	Analyze clinically relevant misclassifications between similar disorders
Comparison methods	Classical ML baselines	Logistic Regression, SVM, Random Forest, k-NN, Naïve Bayes	Benchmark proposed AI models against traditional clinical ML approaches
	Deep learning baselines	CNN, LSTM, GRU, transformer-based models	Compare advanced architectures used for speech, text, EEG, or imaging data
	Modality-wise comparison	Unimodal vs multimodal models (text, speech, physiological signals, neuroimaging)	Quantify the benefit of data fusion in mental health assessment
	Ablation studies	Removal of features, modalities, fusion blocks, attention layers, or explainability modules	Examine the contribution of individual components to diagnostic performance
	Statistical significance testing	Paired t-test, Wilcoxon signed-rank test (in some studies)	Verify whether performance improvements over baselines are statistically meaningful
Validation strategies	Cross-validation	5-fold and 10-fold cross-validation	Reduce sampling bias in small and moderate-sized clinical datasets
	Stratified validation	Stratified k-fold cross-validation	Preserve class distribution for imbalanced mental health datasets
	Hold-out validation	Train / validation / test split	Standard evaluation in larger datasets
	Subject-wise validation	Subject-level or session-wise splits	Prevent data leakage when multiple records per participant are available
	External validation	Independent datasets from different institutions or cohorts	Assess generalizability and real-world clinical applicability

	Longitudinal validation	Temporal or follow-up based splitting	Evaluate monitoring and disease progression models
Reliability and robustness checks	Overfitting control	Early stopping, regularization, dropout, repeated cross-validation	Improve model stability and reduce optimistic performance estimates
	Generalizability assessment	Cross-site testing and independent cohort testing	Validate robustness across different populations and acquisition settings

6 **Novelty and Originality**

The establishment of a unified multimodal AI framework that incorporates behavioral, linguistic, physiological, and neuroimaging data to solve the shortcomings of current unimodal techniques documented in earlier literature is what makes this work innovative. Our approach uses a hybrid fusion architecture with attention-based cross-modal learning to enable better representation of mental-health biomarkers, in contrast to other studies that mostly concentrate on single-data sources or depend on simple feature concatenation. By utilizing interpretable AI algorithms and tackling practical problems like class imbalance and missing modalities, this work also improves clinical relevance. Additionally, this research contributes a scalable and generalizable AI-based early-prediction system that connects clinical neuroscience and digital phenotyping by verifying the model across a variety of illnesses and datasets.

Instead of being a technical paper on model development, this paper is organized as a review and perspective article. This paper makes a contribution by providing a synthesized view of the recent artificial intelligence approaches for diagnosis and treatment of mental health conditions across neuroimaging, EEG, speech, language, vision, wearable sensing, and digital health applications. The paper does not propose a new model, dataset, or algorithmic framework. Instead, it offers a consolidated comparative review of the state-of-the-art and state-of-the-practice approaches reported in the literature, identifies key challenges, and outlines the possibilities for future research in mental health applications of artificial intelligence systems.

7 **Conclusion**

This research illustrates how artificial intelligence can transform the diagnosis, monitoring, and treatment of mental health disorders. AI systems provide objective, scalable, and continuous evaluation capabilities, which are largely unattainable with traditional and subjective clinical practices, by analyzing multimodal data, such as speech and text, neuroimaging, clinical records, and digital activity, to mention a few. Evidence indicates that machine learning and deep learning models allow continuous tracking of treatment response, promote early diagnosis of mental health conditions like depression, anxiety, schizophrenia, and Alzheimer's disease (AD), and improve diagnostic accuracy by 10–15%. Multimodal fusion techniques cover the complexity and multidimensional nature of mental health disorders, so tend to do better than unimodal models. The findings also suggest that many barriers will impede broader clinical adoption, even while algorithms perform well in a research setting. There are

ethical concerns to address, such as bias, privacy, and transparency. Many studies are constrained in their generalizability due to small or homogenous samples, or lack of external and prospective validation. Real-world translation is also complicated by inconsistencies around clinical labels, sensor availability, device configurations, and data quality. In addition, physicians need explainable and interpretable output from AI in order to ensure accountability, trust, and safe integration into treatment pathways. This research underscored that AI is indeed a powerful tool for augmentation rather than replacement, and can support decision-making, widen access to treatment, and optimize personalized interventions at scale. Future work must prioritize ethical governance frameworks, cross-institutional datasets, fairness audits, robust validation, and human-centered design if mental healthcare is to incorporate AI innovations into clinical practice. Filling these gaps, AI-enabled mental healthcare has the potential to evolve into a reliable, person-centered ecosystem that supports earlier detection, optimizes treatment pathways, and ultimately improves mental health outcomes around the globe.

Conflict of Interest: The authors declare that they have no conflict of interest.

Funding Declaration: This research did not receive any specific grant from funding agencies in the public, commercial or not-for profit sectors.

Ethics Declaration: Not applicable.

Clinical Trials: Not applicable.

Data Availability Statement: Data will be available upon reasonable request.

References

1. World Health Organization (2022). World Mental Health Report 2022: Transforming mental health for all. WHO Press.
2. Esteva, A., Robicquet, A., Ramsundar, B., Kuleshov, V., DePristo, M., Chou, K., Cui, C., Corrado, G., Thrun, S., & Dean, J. (2019). A guide to deep learning in healthcare. *Nature Medicine*, 25(1), 24–29.
3. Shatte, A. B. R., Hutchinson, D. M., & Teague, S. J. (2019). Machine learning in mental health: a scoping review of methods and applications. *Psychological Medicine*, 49(9), 1426–1448.
4. Kalmady, S. V., Greiner, R., Agrawal, R., Shivakumar, V., Narayanaswamy, J. C., Brown, M. R. G., Greenshaw, A. J., Dursun, S. M., & Venkatasubramanian, G. (2019). Towards artificial intelligence in mental health by improving schizophrenia prediction with multiple brain parcellation ensemble-learning. *NPJ Schizophrenia*, 5(1), Article 2.
5. Inkster, B., Kadaba, M., & Subramanian, V. (2023). Understanding the impact of an AI-enabled conversational agent mobile app on users' mental health and

wellbeing with a self-reported maternal event: A mixed-method real-world data mHealth study. *Frontiers in Global Women's Health*, 4, Article 1084302

6. Li, H., et al. (2023). Systematic review and meta-analysis of AI-based conversational agents for improving mental health outcomes. *npj Digital Medicine*.
7. Riad, R., et al. (2024). Automated speech analysis for detecting depression, anxiety, insomnia, and fatigue: Algorithm development and validation. *Journal of Medical Internet Research*, 26, e58572.
8. Shen, Y., et al. (2025). Passive sensing and machine learning for mental health: A systematic review of smartphones and wearables. *BMC Psychiatry*.
9. Akre, E., et al. (2024). Improving rigor, equity, and impact in digital mental health sensing research. Workshop Report.
10. Bauer, M., et al. (2024). Machine-learning analysis of clinical speech for longitudinal monitoring of major depressive disorder. *Journal of Psychiatric Research*.
11. Ahmed, S., et al. (2023). Rapid, low-burden AI system for depression screening: A lightweight multimodal approach. *Journal of Affective Disorders*.
12. Wang, L., Wang, C., Li, C., Murai, T., Bai, Y., Song, Z., Zhang, S., Zhang, Q., Huang, Y., Bi, X., & Jiang, J. (2025). AI-assisted multi-modal information for the screening of depression: a systematic review and meta-analysis. *npj Digital Medicine*, 8, 523
13. Karlin, B., Henry, D., Anderson, R., Cieri, S., Aratow, M., Shriberg, E., & Hoy, M. (2025). Digital phenotyping for detecting depression severity in a large payor-provider system: Retrospective study of speech and language model performance. *JMIR AI*, 4, e69149
14. Torous, J., et al. (2025). Evidence and translational barriers in digital and AI-assisted mental health care. *Nature Mental Health*.
15. Cruz-Gonzalez, R., et al. (2025). Artificial intelligence for mental health diagnosis, monitoring, and intervention: A systematic review. *Scientific Reports*.
16. Huang, X., Wang, F., Gao, Y., Liao, Y., Zhang, W., Zhang, L., & Xu, Z. (2024). Depression recognition using voice-based pre-training model. *Scientific Reports*, 14(1), 12,734.
17. Olawade, K., et al. (2024). AI in mental health: Ethical issues, challenges, and future directions. *Current Psychiatry Reports*.
18. Teferra, B. G., Rueda, A., Pang, H., Valenzano, R., Samavi, R., Krishnan, S., & Bhat, V. (2024). Screening for Depression Using Natural Language Processing: Literature Review. *Interactive Journal of Medical Research*, 13, e55067.
19. Ahmed, I., Brahmacharimayum, A., Ali, R. H., Khan, T. A., & Ahmad, M. O. (2025). Explainable AI for Depression Detection and Severity Classification From Activity Data: Development and Evaluation Study of an Interpretable Framework. *JMIR Mental Health*, 12, e72038.
20. Li, S., & Xiao, Y. (2024). Depression detection via cross-attention multimodal fusion. *arXiv preprint*.
21. Kapitány-Fövény, M., Vetró, M., Révy, G., Fabó, D., Szirmai, D., & Hullám, G. (2024). EEG based depression detection by machine learning: Does inner or overt

- speech condition provide better biomarkers when using emotion words as experimental cues? *Journal of Psychiatric Research*, 178, 66–76.
22. Arya AD, V. S. (2023). A systematic review on machine learning and deep learning techniques in the effective diagnosis of Alzheimer's disease. *Brain Inform.*
 23. Frnaz Akbar, I. T. (2025). Unlocking the potential of EEG in Alzheimer's disease research: Current status and pathways to precision detection. *Brain Research Bulletin*.
 24. Choi A, O. A. (2024). Digital Phenotyping for Stress, Anxiety, and Mild Depression: Systematic Literature Review. *JMIR Mhealth Uhealth*.
 25. Pigoni, A. D. (2024). Machine learning and the prediction of suicide in psychiatric populations: a systematic review. . *Transl Psychiatry* 14.
 26. Ding, K. C. (2024). Speech based detection of Alzheimer's disease: a survey of AI techniques, datasets and challenges. *Artif Intell Rev* 57, 325.
 27. Walambe, R., Nayak, P., Bhardwaj, A., & Kotecha, K. (2023). Employing Multimodal Machine Learning for Stress Detection. *arXiv preprint. arXiv*
 28. Smith, A. B., et al. (2024). Machine Learning for Multimodal Mental Health Detection: A Systematic Review of Passive Sensing Approaches. *Journal name. PubMed*
 29. Jones, C., & Wang, Y. (2025). Artificial intelligence in mental health: integrating opportunities and challenges of multimodal deep learning for mental disorder prevention and treatment. *Journal name. PubMed*
 30. Brown, D., et al. (2025). Classification of neurological and mental health disorders based on multimodal approaches: A comprehensive review. *Journal name.*
 31. Zhang, G., Nie, X., Liu, B., Yuan, H., Li, J., Sun, W., & Huang, S. (2023). A multimodal fusion method for Alzheimer's disease based on DCT convolutional sparse representation. *Frontiers in Neuroscience*, 16:1100812. <https://doi.org/10.3389/fnins.2022.1100812>.
 32. Wang, J., Wen, S., Liu, W., Meng, X., & Jiao, Z., et al. (2024). Deep joint learning diagnosis of Alzheimer's disease based on multimodal feature fusion. *BioData Mining*, 17, Article 48. <https://doi.org/10.1186/s13040-024-00395-9>.
 33. Odusami, M., et al. (2023). Explainable deep-learning-based diagnosis of Alzheimer's disease using multimodal input fusion of PET and MRI images. *Journal of Medical and Biological Engineering*. <https://doi.org/10.1007/s40846-023-00801-3>
 34. Bufano, P., et al. (2023). Digital phenotyping for monitoring mental disorders: Systematic review. *Journal of Medical Internet Research*, 25, e46778.
 35. Khoo, L. S., Lim, M. K., Chong, C. Y., & McNaney, R. (2024). Machine learning for multimodal mental health detection: A systematic review of passive sensing approaches. *Sensors*, 24(2), 348.
 36. Akbar, F., et al. (2025). Unlocking the potential of EEG in Alzheimer's disease. (Article).

Open Access This chapter is licensed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits any noncommercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.

The images or other third party material in this chapter are included in the chapter's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the chapter's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

